Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Lactobacillus is a genus of probiotic bacteria that has been investigated for its potential to reduce certain side effects of chemotherapy, particularly gastrointestinal symptoms such as diarrhea and mucositis. Chemotherapy can disrupt the gut microbiota, leading to inflammation, infection, and impaired gut function. Several randomized controlled trials and meta-analyses have explored the use of probiotics, including Lactobacillus strains, to mitigate these adverse effects.

Evidence suggests that specific Lactobacillus strains (often combined with other probiotic species) can decrease the incidence and severity of chemotherapy-induced diarrhea, especially in patients with colorectal cancer undergoing fluorouracil-based regimens. Some studies also report reduced risk of severe oral mucositis. The proposed mechanisms include restoration of gut microbial balance, strengthening of the intestinal barrier, and modulation of the immune response.

However, results are not universally consistent across all studies. The efficacy appears to depend on the specific strain(s), dosage, and patient population. Safety is generally good, but there are rare case reports of infections in severely immunocompromised patients.

In summary, there is moderate scientific evidence supporting the use of Lactobacillus-containing probiotics to reduce certain chemotherapy side effects, primarily diarrhea. Guidelines from some oncology societies cautiously acknowledge their potential benefit, while calling for further high-quality research.

More about Lactobacillus
More about Chemotherapy (reducing side effects)

Other ingredients used for Chemotherapy (reducing side effects)

Other health conditions supported by Lactobacillus

Products containing Lactobacillus